A comparative analysis of ACE Inhibitors and ARBs as cancer risk factors
Belle Tamir Brahms, Shani Afek, Michael Hopp, Martine Granek-Catarivas, Yair Levy, Tzipi Hornik-Lurie · 2026
Read A comparative analysis of ACE Inhibitors and ARBs as cancer risk factors by Belle Tamir Brahms, Shani Afek, Michael Hopp, Martine Granek-Catarivas, Yair Levy, Tzipi Hornik-Lurie (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0354248.txt.
Description
Brahms and colleagues, in a 2026 study, compare two huge families of blood pressure drugs for a possible link to cancer. Both families are mainstays of heart and kidney care, yet their long-term safety on cancer has stayed unsettled. Using records from Israel's largest health service, the team followed adults with high blood pressure who stayed on one family only.
From a pool of over a million people, rules left about three hundred fifty thousand users of one family and seventy-seven thousand of the other. Over long follow-up, cancer appeared less often among users of the first family, the ACE inhibitors, than among users of the second, the receptor blockers. The pattern shifted by cancer type, favoring the first family for several common cancers. The authors stress the design cannot prove cause, since doctors choose drugs for reasons that may track with cancer risk.
Catalog record
| CREATOR | Belle Tamir Brahms, Shani Afek, Michael Hopp, Martine Granek-Catarivas, Yair Levy, Tzipi Hornik-Lurie |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 24334 |
| LICENSE | CC_BY |
| RIGHTS | CC BY |
| SOURCE | PLOS |